SEQENS is involved in the development and production of pharmaceutical solutions, personal care ingredients, and custom specialty chemical products.

SEQENS

Beiersdorf Aktiengesellschaft engages in the manufacture and distribution of consumer goods in Europe, the Americas, Africa, Asia, and Australia. It operates in two segments, Consumer Business and Tesa Business. The Consumer Business Segment offers skin and body care products. The Tesa Business segment provides adhesive tapes and self-adhesive products and system solutions for industries, craft businesses, and consumers. This segment offers its system solutions to the automotive, electronics, printing and paper, and building and construction industries. It offers its products under the NIVEA, Eucerin, La Prairie, Labello, Hansaplast, 8x4, FLORENA, Coppertone, HIDROFUGAL, GAMMON, SKIN STORIES, FLORENA FERMENTED SKINCARE, STOP THE WATER WHILE USING ME, CHAUL, TESA, O.W.N., Chantecaille, Elastoplast, CURITAS, and Beiersdorf brands. The company was founded in 1882 and is headquartered in Hamburg, Germany. Beiersdorf Aktiengesellschaft is a subsidiary of maxingvest ag.

Beiersdorf Aktiengesellschaft

Biogenesis Healthcare is a Greek biopharmaceutical company focused on providing innovative treatment solutions for severe, chronic, and rare diseases.  Biogenesis Healthcare aims to collaborate with multinational companies to distribute specialty and rare disease products, particularly those with completed Phase III clinical trials and pending or expected FDA and EMA marketing authorizations.

Biogenesis Healthcare

Cohere Beauty is a contract manufacturer specializing in the development and manufacturing of personal care products, including haircare, skincare, bodycare, and fragrance. They focus on innovation, expertise, and quality assurance in product development.

Metric
Company Name	SEQENS	Beiersdorf Aktiengesellschaft	Biogenesis Healthcare	Cohere Beauty
Symbol		BEI
MSH ID	COM:SEQENS	COM:BEIERSDORF	COM:BIOGENESIS-HEALTHCARE	COM:COHEREBEAUTY
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Consumer Defensive	Healthcare & Health Services	Consumer Goods
Industry	Pharmaceuticals	Household & Personal Products	Pharmaceuticals	Cosmetics & Personal Care
Country	FR	DE	GR	US
Stage
Employee Count		21.96K
Website	seqens.com	beiersdorf.com	biogenesis-healthcare.com	coherebeauty.com
LinkedIn		beiersdorf
Founders

Metric
Market Cap		32.28B
Enterprise Value
Monthly Web Traffic	12.44K
Web Traffic Growth	-0.71
Valuation
Raised Capital

Metric
Revenue		9.98B
Revenue (LTM)
Revenue (NTM)
Gross Profit		5.54B
EBITDA		1.55B
Operating Income		1.25B
Net Income		777.39M
EPS		3.42
Diluted EPS		3.42
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.58
Operating Profit Margin		0.14
EBITDA Margin		0.16
Net Profit Margin		0.08
Return on Equity		0.09
Return on Assets		0.06
Return on Capital Employed		0.14

COM:SEQENS

SEQENS

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		82.64
P/B Ratio		3.90
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		3.48
EV Multiple		19.58

Metric
Days Sales Outstanding		190.49
Days Payables Outstanding		484.89
Days Inventory Outstanding		137.09
Operating Cycle		231.24
Cash Conversion Cycle		5.32
Asset Turnover		0.74

Metric
Operating Cash Flow		1.03B
Free Cash Flow		481.64M
Cash Flow to Debt		9.54
Operating Cash Flow/Sales		0.13
Free Cash Flow Yield		0.00

Metric
Cash & Equivalents		1.20B
Accounts Receivable
Inventory		1.60B
Goodwill		617.89M
Debt to Capitalization		0.05
Debt to Assets
Current Ratio		1.60
Quick Ratio		1.34

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.03
SG&A to Revenue		0.40